Eli Lilly's Q3 revenue and earnings
Statements (10 of 15)
- Bullish
Eli Lilly reported a third-quarter earnings beat driven by its GLP-1 portfolio.
- Bullish
Eli Lilly reported a blowout quarter, indicating strong financial performance.
- Bullish
Eli Lilly reported a 39% increase in Q3 sales compared to the prior year.
- Bullish
Eli Lilly reported third-quarter revenue of $24.4 billion, exceeding consensus estimates by $1.8 billion.
- Bearish
Eli Lilly's realized prices fell 15% as sales volume increased 53% year over year.
- Bullish
Eli Lilly's third-quarter net income increased 16% year over year.
- Bullish
Eli Lilly reported third-quarter revenue growth and raised its sales guidance.
- Bearish
Eli Lilly's projected operating income is expected to decrease slightly.
- Bullish
Eli Lilly's revenue for the third quarter of fiscal 2026 climbed 39% compared to the same period a year ago to reach $24.4 billion
- Bearish
Eli Lilly's earnings per share estimate collapsed by a third in just 30 days
5 more statements on this development this week. The API returns all of them: GET /v2/statements?topic_id=fbc21018-9cf5-48ab-a38e-48f01f631919 Get a free API key ↗